MARKET TALK: AstraZeneca Boost Seen On Brilinta Hopes

27th Jul 2010 11:34

1034 GMT [Dow Jones] Panmure Gordon & Co analyst Savvas Neophytou says AstraZeneca PLC's (AZN) shares to rise Tuesday on U.S. Food and Drug Administration documents, released ahead of a Wednesday advisory panel, which raises hopes for its experimental blood thinner Brilinta. "Our reading of the key sections of the briefing document guides us towards a very benign criticism of the product...Some analysts had expected the agency to request further trials in U.S. patients before approval, so a positive endorsement on Wednesday should go a long way towards triggering upgrades," says analyst, who re-iterates buy recommendation and 3600p price target. Shares +3.0% at 3219p. ([email protected]) Contact us in London. +44-20-7842-9464 [email protected] (END) Dow Jones Newswires July 27, 2010 06:34 ET (10:34 GMT)